Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

1.0K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncologyยท2026
Same author

The long-term efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in the treatment of primary central nervous system lymphoma: A real-world report from the Polish Lymphoma Research Group.

European journal of cancer (Oxford, England : 1990)ยท2026
Same author

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4ยท5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

Lancet (London, England)ยท2026
Same author

Granulocyte differentiation arrest in HAX1-deficient cells, demonstrated in a new in vitro model of a certain phenotypic aspects of Kostmann disease, is caused by ineffective lipid droplet autophagy and fatty acids uptake.

Cell death & diseaseยท2026
Same author

Epstein-Barr Virus-positive NK/T-cell Malignancies in Poland: Distinctive Features, Therapeutic Strategies, and Survival Insights-The Real-world Retrospective Report of the Polish Lymphoma Research Group.

Asia-Pacific journal of clinical oncologyยท2026
Same author

Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.

The Lancet. Haematologyยท2026

Related Experiment Video

Updated: Jul 28, 2025

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

10.1K

New molecular targets in Hodgkin and Reed-Sternberg cells.

Hummaira Sadaf1,2, Maciej Ambroziak1, Robert Binkowski3

  • 1Department of Experimental Immunotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.

Frontiers in Immunology
|June 2, 2023
PubMed
Summary

Understanding classical Hodgkin lymphoma (HL) requires exploring molecular mechanisms. Research into cluster of differentiation molecule 30 (CD30), programmed cell death-1 protein (PD-1), and epigenetic modifiers is key for new targeted therapies.

Keywords:
CD30Hodgkin lymphomaPD-1PD-L1Reed-Sternberg cellschromatin remodelingncRNA

More Related Videos

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

891
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

21.1K

Related Experiment Videos

Last Updated: Jul 28, 2025

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

10.1K
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

891
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

21.1K

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Classical Hodgkin lymphoma (HL) involves specific molecular alterations in Hodgkin and Reed-Sternberg (HRS) cells.
  • Current understanding of HL pathogenesis is incomplete despite available molecular data.

Purpose of the Study:

  • To summarize current knowledge on molecular mechanisms in HL development and progression.
  • To review existing and potential targeted therapies for HL.
  • To propose future research directions for identifying novel molecular targets.

Main Methods:

  • Review of recent discoveries on molecular mechanisms in HL.
  • Discussion of key molecules like cluster of differentiation molecule 30 (CD30) and programmed cell death-1 protein (PD-1) and its ligands (PD-L1/2).
  • Highlighting the role of epigenetic modifiers, including SWI/SNF and PRC2 complexes.

Main Results:

  • Characteristic molecular alterations in HL include dysregulation of CD30, PD-1/PD-L1 pathways, and epigenetic modifiers.
  • Altered chromatin remodeling complexes and epigenetic modifiers contribute to HL-specific chromatin states.
  • Immune modulation pathways are critical in HL pathogenesis.

Conclusions:

  • Further research into PD-1/PD-L1 reverse signaling, chromatin remodeling, and epigenetics is needed for a comprehensive understanding of HL.
  • Identifying novel molecular targets through advanced research can lead to more effective targeted therapies for HL.
  • Continued molecular investigation is crucial for advancing HL treatment strategies.